Pemvidutide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Pemvidutide evidence and protocol review

Metabolic Research peptide Lyophilized verified

Also known as: ALT-801

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

5 mg, 10 mg, 20 mg

Calculator

Preset available

Storage

Investigational compound - no FDA label. Use source COA / vendor storage guidance and verify independently before recording.

Solubility

Aqueous injectable solution; peptide with proprietary half-life extension

Catalog Description

Pemvidutide is an investigational balanced GLP-1/glucagon dual receptor agonist. Phase 2 studies reported weight and liver-marker findings, and the FDA granted Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis. Phase 3 development has been announced, but the compound is not approved.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Supports weekly dosing in Phase 2b trials (specific published half-life not yet corroborated by two independent sources)

Onset

Effects on liver markers reported at 24-48 weeks in Phase 2b (IMPACT) trial

Administration Routes (Research)

Reported Research Effects

Improves noninvasive liver fibrosis/fat markers in MASLD/MASH trial population
Weight reduction consistent with dual GLP-1/glucagon mechanism

Reported Research Side Effects

Human safety, pharmacokinetics, and interaction data are incomplete

Data source: Clinical trial registry, peer-reviewed research, and patent record

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

1.2 mg target arm: 1.2 mg once weekly without titration [SC; 48-week Phase 2 MOMENTUM regimen; Weekly]Source: MOMENTUM trial
1.8 mg target arm: 1.8 mg once weekly without titration [SC; 48-week Phase 2 MOMENTUM regimen; Weekly]Source: MOMENTUM trial
2.4 mg target arm: 4-week rapid titration followed by 2.4 mg once weekly; public primary summaries do not specify the intermediate titration dose [SC; 48-week Phase 2 MOMENTUM regimen; Weekly]Source: MOMENTUM trial and pemvidutide regimen patent

Research Notes

Pemvidutide is investigational. The 1.2 mg and 1.8 mg MOMENTUM arms used no titration; the 2.4 mg arm used a short four-week titration, but available primary public summaries do not identify a single intermediate dose, so none is invented here.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

MOMENTUM pemvidutide Phase 2 study — ClinicalTrials.gov
https://clinicaltrials.gov/study/NCT05006885

Pemvidutide therapeutic regimens patent — Google Patents
https://patents.google.com/patent/WO2025193765A1/en

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.